CHILDREN'S ALLEGRA ALLERGY

Peak

fexofenadine hydrochloride

Sanofi
NDAORALSUSPENSION
Approved
Jan 2011
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
3

Indications (4)

these symptoms due to hay feverother upper respiratory allergies: runny nose sneezing itchywater eyes itching of the nosethroat

Clinical Trials (3)

NCT05720455Phase 4Completed

Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above

Started Jun 2025
203 enrolled
Rhinitis Allergic
NCT00835276Phase 1Completed

Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions

Started Mar 2002
60 enrolled
Healthy
NCT00835640Phase 1Completed

Fexofenadine Hydrochloride 180 mg Tablets Under Non-Fasting Conditions

Started Jan 2002
24 enrolled
Healthy

Loss of Exclusivity

LOE Date
Aug 2, 2030
53 months away
Patent Expiry
Aug 2, 2030

Patent Records (1)

Patent #ExpiryTypeUse Code
8933097
Aug 2, 2030
Product
—
Company
Sanofi
Sanofi
PARIS, France
1139 open jobs
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers